Synthoplate: intravenous hemostatic nanotechnology to mitigate bleeding in thrombocytopenia

Ended Project Grant Awarded Last action

Award ID
R44HL145948
Recipient
Awarding agency
Obligated
$8,285,089

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Originally
Place of performance
Ohio, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The normal platelet count in human blood is 150,000-400,000/ΜL, and these platelets are responsible for efficient hemostatic surveillance and bleeding mitigation in the body. Thrombocytopenia (TCP, low platelet count) is a condition caused by a decrease in platelet production, increase in platelet destruction or consumption, or increase in splenic sequestration. The age-adjusted prevalence of immune thrombocytopenic purpura (ITP) is estimated to be 3.3 per 100,000 persons in the USA, while drug-induced TCP affects 1-2 per 100,000 persons. The majority (>95%) of TCP cases result from autoimmune disorders or are induced by chemo- and radiotherapies as well as other pharmaceuticals. At platelet counts

Transactions

Action Obligated Date
Amendment -$19,767
Amendment $0
Amendment $50,000
Amendment $50,000
Amendment $112,804
Amendment $112,804
Amendment $112,804
Amendment $972,163
Amendment $972,163
Amendment $972,163
Amendment $972,163
Amendment $0
Amendment $0
Amendment $0
Amendment $994,448
Amendment $994,448
Amendment $994,448
Original award $994,448
Show all 18

Quick answers

Who received award R44HL145948?

R44HL145948 was awarded to Haima Therapeutics LLC by National Heart Lung and Blood Institute (National Institutes of Health) on June 1, 2019.

How much is award R44HL145948 worth?

$8,285,089 has been obligated on R44HL145948.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login